Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PRPO – Precipio Inc

Float Short %

0.67

Margin Of Safety %

-28

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

6.25

Price

14.25

Target Price

19

Analyst Recom

1

Performance Q

44.04

Relative Volume

0.4

Beta

1.09

Ticker: PRPO




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25PRPO14.7N/AN/A0
2025-07-28PRPO14.4N/AN/A0
2025-07-29PRPO14.45N/AN/A0
2025-07-30PRPO14.4884N/AN/A0
2025-07-31PRPO14.26N/AN/A0
2025-08-01PRPO14.46N/AN/A0
2025-08-04PRPO14.2N/AN/A0
2025-08-05PRPO14.21N/AN/A0
2025-08-06PRPO14.58N/AN/A0
2025-08-07PRPO14.2N/AN/A0
2025-08-08PRPO13.9N/AN/A0
2025-08-11PRPO13.8N/AN/A0
2025-08-12PRPO14.08N/AN/A0
2025-08-13PRPO14.24N/AN/A0
2025-08-14PRPO14.7N/AN/A0
2025-08-15PRPO14.7N/AN/A0
2025-08-18PRPO14.18N/AN/A0
2025-08-19PRPO14N/AN/A0
2025-08-20PRPO14.54N/AN/A0
2025-08-21PRPO14.5N/AN/A0
2025-08-22PRPO14.3N/AN/A0
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25PRPO14.70- - -6.25
2025-07-28PRPO14.76- - -6.25
2025-07-29PRPO14.45- - -6.25
2025-07-30PRPO14.48- - -6.25
2025-07-31PRPO14.26- - -6.25
2025-08-01PRPO14.46- - -6.25
2025-08-04PRPO14.51- - -6.25
2025-08-05PRPO14.65- - -6.25
2025-08-06PRPO14.07- - -6.25
2025-08-07PRPO14.20- - -6.25
2025-08-08PRPO13.90- - -6.25
2025-08-11PRPO13.90- - -6.25
2025-08-12PRPO13.98- - -6.25
2025-08-13PRPO14.29- - -6.25
2025-08-14PRPO14.58- - -6.25
2025-08-15PRPO14.69- - -6.25
2025-08-18PRPO14.11- - -6.25
2025-08-19PRPO14.30- - -6.25
2025-08-20PRPO14.40- - -6.25
2025-08-21PRPO14.59- - -6.25
2025-08-22PRPO14.25- - -6.25
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25PRPO6.9648.291.19
2025-07-28PRPO6.9649.771.19
2025-07-29PRPO6.8849.771.19
2025-07-30PRPO6.8949.771.19
2025-07-31PRPO6.8949.771.19
2025-08-01PRPO6.8949.771.19
2025-08-04PRPO6.8952.541.19
2025-08-05PRPO6.8952.541.19
2025-08-06PRPO6.8952.541.19
2025-08-07PRPO6.8952.541.19
2025-08-08PRPO6.8852.541.19
2025-08-11PRPO6.8858.141.19
2025-08-12PRPO6.8858.140.71
2025-08-13PRPO6.8858.140.71
2025-08-14PRPO6.8958.140.71
2025-08-15PRPO6.8858.140.71
2025-08-18PRPO6.40-8.320.67
2025-08-19PRPO6.40-8.320.67
2025-08-20PRPO6.32-8.320.67
2025-08-21PRPO6.40-8.320.67
2025-08-22PRPO6.40-8.320.67
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.93

Avg. EPS Est. Next Quarter

Insider Transactions

6.4

Institutional Transactions

-8.32

Beta

1.09

Average Sales Estimate Current Quarter

4

Average Sales Estimate Next Quarter

Fair Value

10.23

Quality Score

45

Growth Score

55

Sentiment Score

82

Actual DrawDown %

92.2

Max Drawdown 5-Year %

-95.8

Target Price

19

P/E

Forward P/E

PEG

P/S

1.09

P/B

1.76

P/Free Cash Flow

41.23

EPS

-1.21

Average EPS Est. Cur. Y​

-6.25

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-8.48

Relative Volume

0.4

Return on Equity vs Sector %

-39.3

Return on Equity vs Industry %

-25.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Precipio, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 54
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
stock quote shares PRPO – Precipio Inc Stock Price stock today
news today PRPO – Precipio Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PRPO – Precipio Inc yahoo finance google finance
stock history PRPO – Precipio Inc invest stock market
stock prices PRPO premarket after hours
ticker PRPO fair value insiders trading

PRPH – ProPhase Labs Inc

Float Short %

0.37

Margin Of Safety %

Put/Call OI Ratio

0.01

EPS Next Q Diff

-0.01

EPS Last/This Y

2.05

EPS This/Next Y

Price

0.33

Target Price

16

Analyst Recom

1

Performance Q

7.1

Relative Volume

0.1

Beta

-0.78

Ticker: PRPH




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25PRPH0.45990.010.005795
2025-07-28PRPH0.450.010.027578
2025-07-29PRPH0.35130.010.047753
2025-07-30PRPH0.35130.010.007851
2025-07-31PRPH0.35780.010.088059
2025-08-01PRPH0.32610.010.008180
2025-08-04PRPH0.31250.010.008372
2025-08-05PRPH0.31380.010.008484
2025-08-06PRPH0.31240.010.008494
2025-08-07PRPH0.32220.010.008583
2025-08-08PRPH0.31710.010.008795
2025-08-11PRPH0.27820.010.008949
2025-08-12PRPH0.3520.010.039246
2025-08-13PRPH0.3250.010.0111113
2025-08-14PRPH0.33860.010.0011608
2025-08-15PRPH0.34020.010.1011830
2025-08-18PRPH0.340.010.0010636
2025-08-19PRPH0.31260.010.0010908
2025-08-20PRPH0.32980.010.0010947
2025-08-21PRPH0.33980.010.0111122
2025-08-22PRPH0.33160.010.0011331
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25PRPH0.4754.6- -0.56
2025-07-28PRPH0.4554.6- -0.56
2025-07-29PRPH0.3554.6- -0.56
2025-07-30PRPH0.3654.6- -0.56
2025-07-31PRPH0.3654.6- -0.56
2025-08-01PRPH0.3354.6- -0.56
2025-08-04PRPH0.3154.6- -0.56
2025-08-05PRPH0.3154.6- -0.56
2025-08-06PRPH0.3154.6- -0.56
2025-08-07PRPH0.3354.6- -0.56
2025-08-08PRPH0.3154.6- -0.56
2025-08-11PRPH0.2854.6- -0.56
2025-08-12PRPH0.3554.6- -0.56
2025-08-13PRPH0.3354.6- -0.56
2025-08-14PRPH0.3354.6- -0.56
2025-08-15PRPH0.3454.6- -0.56
2025-08-18PRPH0.3454.6- -0.56
2025-08-19PRPH0.3154.6- -0.56
2025-08-20PRPH0.3354.6- -0.56
2025-08-21PRPH0.3354.6- -0.56
2025-08-22PRPH0.3368.6- -0.56
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25PRPH0.0092.200.39
2025-07-28PRPH0.0091.230.39
2025-07-29PRPH0.0091.230.39
2025-07-30PRPH0.0091.230.39
2025-07-31PRPH0.0091.230.39
2025-08-01PRPH0.0091.230.39
2025-08-04PRPH0.0088.780.39
2025-08-05PRPH0.0088.780.39
2025-08-06PRPH0.0088.780.39
2025-08-07PRPH0.0088.780.39
2025-08-08PRPH0.0088.780.39
2025-08-11PRPH0.0095.110.39
2025-08-12PRPH0.0095.110.37
2025-08-13PRPH0.0095.110.37
2025-08-14PRPH0.0095.110.37
2025-08-15PRPH0.0095.110.37
2025-08-18PRPH0.0081.730.37
2025-08-19PRPH0.0081.730.37
2025-08-20PRPH0.0081.730.37
2025-08-21PRPH0.0081.730.37
2025-08-22PRPH0.0081.730.37
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.11

Avg. EPS Est. Current Quarter

-0.11

Avg. EPS Est. Next Quarter

-0.12

Insider Transactions

Institutional Transactions

81.73

Beta

-0.78

Average Sales Estimate Current Quarter

5

Average Sales Estimate Next Quarter

9

Fair Value

Quality Score

23

Growth Score

29

Sentiment Score

82

Actual DrawDown %

97.9

Max Drawdown 5-Year %

-98.4

Target Price

16

P/E

Forward P/E

PEG

P/S

1.07

P/B

1.19

P/Free Cash Flow

EPS

-1.5

Average EPS Est. Cur. Y​

-0.56

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-217.64

Relative Volume

0.1

Return on Equity vs Sector %

-387.2

Return on Equity vs Industry %

-373.2

EPS 1 7Days Diff

EPS 1 30Days Diff

0.24

EBIT Estimation

ProPhase Labs, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 96
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
stock quote shares PRPH – ProPhase Labs Inc Stock Price stock today
news today PRPH – ProPhase Labs Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PRPH – ProPhase Labs Inc yahoo finance google finance
stock history PRPH – ProPhase Labs Inc invest stock market
stock prices PRPH premarket after hours
ticker PRPH fair value insiders trading

NEO – Neogenomics Inc.

Float Short %

4.01

Margin Of Safety %

Put/Call OI Ratio

0.33

EPS Next Q Diff

0.11

EPS Last/This Y

0.72

EPS This/Next Y

0.1

Price

6.61

Target Price

8.1

Analyst Recom

2.33

Performance Q

-9.27

Relative Volume

0.83

Beta

1.55

Ticker: NEO




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25NEO6.290.280.0719567
2025-07-28NEO6.470.280.1519633
2025-07-29NEO5.260.270.5820602
2025-07-30NEO5.090.280.0425573
2025-07-31NEO4.840.260.1225695
2025-08-01NEO5.170.260.9425902
2025-08-04NEO5.670.322.7626096
2025-08-05NEO5.620.310.0125598
2025-08-06NEO5.50.310.0025547
2025-08-07NEO5.770.300.0226323
2025-08-08NEO5.80.300.0526284
2025-08-11NEO5.840.300.1026297
2025-08-12NEO6.090.300.7226296
2025-08-13NEO6.240.300.0126354
2025-08-14NEO6.180.300.0726226
2025-08-15NEO6.20.300.0026220
2025-08-18NEO6.240.330.1719343
2025-08-19NEO6.310.330.0019388
2025-08-20NEO6.090.330.0119510
2025-08-21NEO6.180.330.0619652
2025-08-22NEO6.610.330.0519678
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25NEO6.29-15.4- 0.16
2025-07-28NEO6.47-17.9- 0.16
2025-07-29NEO5.25-17.9- 0.16
2025-07-30NEO5.10-17.9- 0.16
2025-07-31NEO4.84-17.9- 0.16
2025-08-01NEO5.16-43.1- 0.11
2025-08-04NEO5.67-43.1- 0.11
2025-08-05NEO5.62-43.1- 0.11
2025-08-06NEO5.49-43.1- 0.11
2025-08-07NEO5.76-43.1- 0.11
2025-08-08NEO5.80-43.1- 0.10
2025-08-11NEO5.83-52.3- 0.10
2025-08-12NEO6.09-52.3- 0.10
2025-08-13NEO6.24-52.3- 0.10
2025-08-14NEO6.18-52.3- 0.10
2025-08-15NEO6.20-52.3- 0.10
2025-08-18NEO6.24-52.3- 0.10
2025-08-19NEO6.31-52.3- 0.10
2025-08-20NEO6.09-52.3- 0.10
2025-08-21NEO6.18-52.3- 0.10
2025-08-22NEO6.61-52.3- 0.10
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25NEO4.422.783.37
2025-07-28NEO4.42-4.133.37
2025-07-29NEO4.42-4.133.37
2025-07-30NEO4.42-4.133.37
2025-07-31NEO4.42-4.133.37
2025-08-01NEO4.40-4.133.35
2025-08-04NEO4.40-4.083.35
2025-08-05NEO4.40-4.083.35
2025-08-06NEO6.77-4.083.35
2025-08-07NEO6.52-4.083.36
2025-08-08NEO6.52-4.083.36
2025-08-11NEO6.52-4.083.35
2025-08-12NEO7.04-4.083.94
2025-08-13NEO7.04-4.083.94
2025-08-14NEO7.04-4.083.94
2025-08-15NEO7.04-4.083.94
2025-08-18NEO7.04-2.313.94
2025-08-19NEO7.04-2.314.01
2025-08-20NEO2.99-2.314.01
2025-08-21NEO2.99-2.314.01
2025-08-22NEO2.82-2.314.01
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.06

Avg. EPS Est. Current Quarter

0.02

Avg. EPS Est. Next Quarter

0.05

Insider Transactions

2.82

Institutional Transactions

-2.31

Beta

1.55

Average Sales Estimate Current Quarter

183

Average Sales Estimate Next Quarter

189

Fair Value

Quality Score

42

Growth Score

45

Sentiment Score

30

Actual DrawDown %

89.3

Max Drawdown 5-Year %

-91.9

Target Price

8.1

P/E

Forward P/E

36.69

PEG

P/S

1.24

P/B

1

P/Free Cash Flow

EPS

-0.82

Average EPS Est. Cur. Y​

0.1

EPS Next Y. (Est.)

0.2

Target Price Estimates Raised

Target Price Estimates Lowered

1

Profit Margin

-15.1

Relative Volume

0.83

Return on Equity vs Sector %

-36.9

Return on Equity vs Industry %

-22.9

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.06

EBIT Estimation

NeoGenomics, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 2200
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
stock quote shares NEO – Neogenomics Inc. Stock Price stock today
news today NEO – Neogenomics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NEO – Neogenomics Inc. yahoo finance google finance
stock history NEO – Neogenomics Inc. invest stock market
stock prices NEO premarket after hours
ticker NEO fair value insiders trading

MYGN – Myriad Genetics, Inc.

Float Short %

9.63

Margin Of Safety %

Put/Call OI Ratio

0.09

EPS Next Q Diff

0.06

EPS Last/This Y

1.42

EPS This/Next Y

0.1

Price

6.02

Target Price

7.17

Analyst Recom

3.29

Performance Q

53.18

Relative Volume

0.52

Beta

1.87

Ticker: MYGN




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25MYGN4.450.130.043082
2025-07-28MYGN4.390.130.003083
2025-07-29MYGN4.10.130.003085
2025-07-30MYGN4.050.130.023087
2025-07-31MYGN3.840.120.013270
2025-08-01MYGN3.90.120.033300
2025-08-04MYGN3.980.120.103321
2025-08-05MYGN3.860.120.913430
2025-08-06MYGN5.670.120.163455
2025-08-07MYGN6.110.170.266691
2025-08-08MYGN6.320.200.537330
2025-08-11MYGN6.20.210.087192
2025-08-12MYGN6.030.230.047049
2025-08-13MYGN5.880.230.957015
2025-08-14MYGN5.90.220.036971
2025-08-15MYGN5.720.181.308277
2025-08-18MYGN5.720.090.473988
2025-08-19MYGN5.510.080.264061
2025-08-20MYGN5.540.070.024089
2025-08-21MYGN5.820.070.454116
2025-08-22MYGN6.030.090.064182
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25MYGN4.45-122.9122.2-0.01
2025-07-28MYGN4.41-116.0122.1-0.01
2025-07-29MYGN4.10-116.0122.2-0.01
2025-07-30MYGN4.05-116.0122.1-0.01
2025-07-31MYGN3.84-116.0122.2-0.01
2025-08-01MYGN3.91-116.0122.1-0.01
2025-08-04MYGN3.98-116.0122.1-0.01
2025-08-05MYGN3.87-116.0122.2-0.01
2025-08-06MYGN5.68-116.0121.4-0.01
2025-08-07MYGN6.10-116.0122.0-0.01
2025-08-08MYGN6.32-116.0414.8-0.01
2025-08-11MYGN6.20-110.5420.10.00
2025-08-12MYGN6.03-110.5420.10.00
2025-08-13MYGN5.87-110.5420.10.00
2025-08-14MYGN5.89-110.5420.20.00
2025-08-15MYGN5.72-110.5420.10.01
2025-08-18MYGN5.72-120.0420.20.01
2025-08-19MYGN5.51-120.0420.10.01
2025-08-20MYGN5.54-120.0420.20.01
2025-08-21MYGN5.83-120.0420.40.01
2025-08-22MYGN6.02-120.0420.30.01
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25MYGN0.001.738.65
2025-07-28MYGN0.000.818.65
2025-07-29MYGN0.000.818.65
2025-07-30MYGN0.000.818.65
2025-07-31MYGN0.000.818.65
2025-08-01MYGN0.000.818.65
2025-08-04MYGN0.001.278.65
2025-08-05MYGN0.001.278.65
2025-08-06MYGN0.001.278.65
2025-08-07MYGN0.001.278.65
2025-08-08MYGN0.001.278.65
2025-08-11MYGN0.00-0.478.57
2025-08-12MYGN0.00-0.479.63
2025-08-13MYGN0.00-0.479.63
2025-08-14MYGN0.00-0.479.63
2025-08-15MYGN0.00-0.479.63
2025-08-18MYGN0.00-3.669.63
2025-08-19MYGN0.00-3.669.63
2025-08-20MYGN0.00-3.669.63
2025-08-21MYGN0.00-3.669.63
2025-08-22MYGN0.00-3.669.63
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.06

Avg. EPS Est. Current Quarter

-0.01

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-3.66

Beta

1.87

Average Sales Estimate Current Quarter

205

Average Sales Estimate Next Quarter

208

Fair Value

Quality Score

36

Growth Score

39

Sentiment Score

30

Actual DrawDown %

83.7

Max Drawdown 5-Year %

-89.5

Target Price

7.17

P/E

Forward P/E

64.88

PEG

P/S

0.67

P/B

1.44

P/Free Cash Flow

EPS

-4.28

Average EPS Est. Cur. Y​

0.01

EPS Next Y. (Est.)

0.11

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-47.45

Relative Volume

0.52

Return on Equity vs Sector %

-126.5

Return on Equity vs Industry %

-112.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

420.3
Myriad Genetics, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 2700
Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
stock quote shares MYGN – Myriad Genetics, Inc. Stock Price stock today
news today MYGN – Myriad Genetics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MYGN – Myriad Genetics, Inc. yahoo finance google finance
stock history MYGN – Myriad Genetics, Inc. invest stock market
stock prices MYGN premarket after hours
ticker MYGN fair value insiders trading

MTD – Mettler-Toledo International, Inc.

[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol= #%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
[iframe https://api.stockdio.com/visualization/financial/charts/v1/PricesChange?app-key=F086EEE750E14D8D8A456DB88B2D6D8C&symbol= &conditionalVolume=false&allowPeriodChange=false&tooltipsStyle=None&palette=Financial-Light&showBorderAndTitle=false 300 200 ]

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol= 589 360 ]

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

[iframe https://widget.finnhub.io/widgets/recommendation?symbol= 589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol= 589 450 ]
Sector:
Industry:
Employees:
stock quote shares MTD – Mettler-Toledo International, Inc. Stock Price stock today
news today MTD – Mettler-Toledo International, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MTD – Mettler-Toledo International, Inc. yahoo finance google finance
stock history MTD – Mettler-Toledo International, Inc. invest stock market
stock prices premarket after hours
ticker fair value insiders trading

GENE – Genetic Technologies Ltd. ADR

[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=GENE #%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
[iframe https://api.stockdio.com/visualization/financial/charts/v1/PricesChange?app-key=F086EEE750E14D8D8A456DB88B2D6D8C&symbol=GENE &conditionalVolume=false&allowPeriodChange=false&tooltipsStyle=None&palette=Financial-Light&showBorderAndTitle=false 300 200 ]

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

0.76

Target Price

6.87

Analyst Recom

1

Performance Q

-14.99

Relative Volume

Beta

1.11

Ticker: GENE




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25GENE0.765N/AN/A0
2025-07-28GENE0.765N/AN/A0
2025-07-29GENE0.765N/AN/A0
2025-07-30GENE0.765N/AN/A0
2025-07-31GENE0.765N/AN/A0
2025-08-01GENE0.765N/AN/A0
2025-08-04GENE0.765N/AN/A0
2025-08-05GENE0.765N/AN/A0
2025-08-06GENE0.765N/AN/A0
2025-08-07GENE0.765N/AN/A0
2025-08-08GENE0.765N/AN/A0
2025-08-11GENE0.765N/AN/A0
2025-08-12GENE0.765N/AN/A0
2025-08-13GENE0.765N/AN/A0
2025-08-14GENE0.765N/AN/A0
2025-08-15GENE0.765N/AN/A0
2025-08-18GENE0.765N/AN/A0
2025-08-19GENE0.765N/AN/A0
2025-08-20GENE0.765N/AN/A0
2025-08-21GENE0.765N/AN/A0
2025-08-22GENE0.765N/AN/A0
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




No data found




No data found

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=GENE 589 360 ]

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

1.11

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

30

Growth Score

29

Sentiment Score

7

Actual DrawDown %

98.5

Max Drawdown 5-Year %

-97.7

Target Price

6.87

P/E

Forward P/E

PEG

P/S

1.24

P/B

2.89

P/Free Cash Flow

EPS

-1.83

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-156.76

Relative Volume

Return on Equity vs Sector %

-680.2

Return on Equity vs Industry %

-667.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

[iframe https://widget.finnhub.io/widgets/recommendation?symbol=GENE 589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=GENE 589 450 ]
stock quote shares GENE – Genetic Technologies Ltd. ADR Stock Price stock today
news today GENE – Genetic Technologies Ltd. ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch GENE – Genetic Technologies Ltd. ADR yahoo finance google finance
stock history GENE – Genetic Technologies Ltd. ADR invest stock market
stock prices GENE premarket after hours
ticker GENE fair value insiders trading
No more stocks to show